New biopsy technique aims to better spot dangerous prostate cancers

NCT ID NCT06482645

Recruiting now Diagnosis Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a newer biopsy method (perilesional biopsy) can find aggressive prostate cancers as well as the standard combination of targeted and systematic biopsies. About 640 men with a single suspicious MRI lesion will be randomly assigned to one of two biopsy approaches. The goal is to see which method detects clinically significant cancers more accurately while reducing detection of low-risk cancers that don't need treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: biopsy procedure
What this could lead to: If successful, this could help doctors choose the best biopsy method to find aggressive prostate cancers while avoiding unnecessary detection of harmless ones.
What could go wrong: This is a diagnostic study, not a treatment trial. Results may not change practice if the new method misses some cancers or causes more complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Peking University First Hospital
RECRUITING

Beijing, Beijing Municipality, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.